Quantum nonlocality offers a secure way to produce random numbers: Their unpredictability is intrinsic and can be certified just by observing the statistic of the measurement outcomes, without assumptions on how they are produced. To do this, entangled pairs are generated and measured to violate a Bell inequality with the outcome statistics. However, after a projective quantum measurement, entanglement is entirely destroyed and cannot be used again. This fact poses an upper bound to the amount of randomness that can be produced from each quantum state when projective measurements are employed. Instead, by using weak measurements, some entanglement can be maintained and reutilized, and a sequence of weak measurements can extract an unbounded amount of randomness from a single state as predicted in Phys. Rev. A 95, 020102(R) (2017). We study the feasibility of these weak measurements, analyze the robustness to imperfections in the quantum state they are applied to, and then test them using an optical setup based on polarization-entangled photon pairs. We show that the weak measurements are realizable, but can improve the performance of randomness generation only in close-to-ideal conditions.

No abstract

One of the most advanced technologies within the field of quantum mechanics is quantum key distribution (QKD), which allows the secure generation of secret keys among remote users. In order for QKD to be more widely adopted, it must be integrated into existing classical communication systems. However, this can be difficult due to the use of various technologies and channels in deployed networks. Recently, we developed a QKD network in the metropolitan area of Padova, which connects various nodes across the city through a combination of fiber and free-space links. By utilizing a modular design based on the iPOGNAC encoder and the Qubit4Sync method, we have realized portable and adaptable systems that operate in the C and O bands. This allowed us to deploy and test the compatibility of both research and commercial QKD systems by ThinkQuantum with classical communication over a variety of links, as well as their ability to switch between free-space and fiber connections. Finally, we developed and experimentally implemented complex network configurations such as star networks, where a fiber-based transmitter and free-space transmitter could operate with a single receiver.

Intermodal quantum key distribution (IM-QKD) enables the integration of fiber networks and free-space connections, which can be ground-to-ground links or involve satellite nodes in orbit. IM-QKD permits to extend the reach of free-space links without trusting any additional node, but this requires to efficiently couple the free-space signal into a single-mode fiber (SMF). We present the implementation of different IM-QKD networks realized in Padova and Vienna, exploiting km-long deployed fibers and free-space channels up to 620 meters. We show that such an intermodal scheme is compatible with both in-house QKD systems and commercially available solutions exploiting polarization encoding at 1550 nm. Remarkably, we realized different QKD tests in daylight and also in rainy conditions.

Background NGS panels allow the identification of alterations within hundreds of cancer-related genes and can guide a personalized strategy in glioma treatment. Material and Methods From Nov 2019 to Jan 2022 at Veneto Institute of Oncology, Padua, Italy, a large cohort of IDHwt-GBM tissues was analyzed by NGS (FoundationOne®CDx). We identified all potential actionable molecular alterations at diagnosis and/or at recurrence. High tumor mutational burden (TMB) was defined as ≥10 mutations/megabase. Results We analyzed 429 IDHwt-GBM samples: NGS profile was available for 419 samples (97.7%); sample failures in 10 cases (2.3%). 351 (84%) and 68 (16%) GBM samples derived from surgery at diagnosis and recurrence, respectively. All patients received radiotherapy and/or temozolomide as first line therapy. Among all the analyzed samples, the most frequent actionable molecular alterations were: CDKN2A (57%), CDKN2B (53%), EGFR amplification (39%), EGFR mutation (24%), PTEN loss (27%), RB1 (23%), NF1 (18%), PIK3CA (18%), CDK4 (15%), MDM2 (10%), PDGFRA (8%), BRCA1-2 (7%), FGFR1-3 (7%), Myc (6%), JAK (6%), ROS1 (5%), METmut (2%), METampl (2%), BRAF V600E (2%). No NTRK1/2/3 druggable alterations were observed. High TMB was found in 18 samples. The incidence of alteration of EGFR (ampl/mut), RB1, PIK3CA was statistically different between the two subgroups of samples (Fisher test). To date, 10% of patients received a personalized treatment as compassionate use, off-label use or in clinical trials (9 Dabrafenib/Trametinib, 8 Alpelisib, 3 Erdafitinib, 2 Ipatasertib, 1 Alectinib, 1 Capmatinib, 1 Palbociclib, 1 Entrectinib, 1 Pamiparib). Activity analysis is still ongoing. Conclusion NGS is feasible in GBM samples. Potentially, a high rate of patients could receive a personalized treatment. The activity analysis is ongoing. However, the incidence of actionable molecular alterations may differ between diagnosis and recurrent GBM samples.